

# Diana Prieto-Peña

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6494236/publications.pdf>

Version: 2024-02-01

53  
papers

536  
citations

758635

12  
h-index

752256

20  
g-index

55  
all docs

55  
docs citations

55  
times ranked

528  
citing authors

#	ARTICLE	IF	CITATIONS
1	Advances in the Treatment of Giant Cell Arteritis. <i>Journal of Clinical Medicine</i> , 2022, 11, 1588.	1.0	11
2	Angiogenic T Cells: Potential Biomarkers for the Early Diagnosis of Interstitial Lung Disease in Autoimmune Diseases?. <i>Biomedicines</i> , 2022, 10, 851.	1.4	3
3	Utility of tocilizumab in autoimmune eye diseases. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 789-799.	1.4	4
4	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype.. <i>Clinical and Experimental Rheumatology</i> , 2022, , .	0.4	0
5	Clinical and immunological study of Tofacitinib and Baricitinib in refractory Blau syndrome: case report and literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2210932.	1.2	8
6	Epidemiological and genetic features of anti-3-hydroxy-3-methylglutaryl-CoA reductase necrotizing myopathy: Single-center experience and literature review. <i>European Journal of Internal Medicine</i> , 2022, 101, 86-92.	1.0	5
7	The role of PET/CT in the evaluation of patients with large-vessel vasculitis: useful for diagnosis but with potential limitations for follow-up. <i>Rheumatology</i> , 2022, 61, 4587-4589.	0.9	3
8	Combined use of QRISK3 and SCORE as predictors of carotid plaques in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 2801-2807.	0.9	14
9	HLA association with the susceptibility to anti-synthetase syndrome. <i>Joint Bone Spine</i> , 2021, 88, 105115.	0.8	8
10	Tocilizumab in refractory Caucasian Takayasu's arteritis: a multicenter study of 54 patients and literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110209.	1.2	7
11	Predicting the risk of relapse in polymyalgia rheumatica: novel insights. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 225-232.	1.3	5
12	A Review of the Dermatological Complications of Giant Cell Arteritis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2021, Volume 14, 303-312.	0.8	7
13	Treatment With Tofacitinib in Refractory Psoriatic Arthritis: A National Multicenter Study of the First 87 Patients in Clinical Practice. <i>Journal of Rheumatology</i> , 2021, 48, 1552-1558.	1.0	3
14	Tocilizumab in refractory giant cell arteritis. Monotherapy versus combined therapy with conventional immunosuppressive drugs. Observational multicenter study of 134 patients. <i>Seminars in Arthritis and Rheumatism</i> , 2021, 51, 387-394.	1.6	13
15	BAFF, APRIL and BAFFR on the pathogenesis of Immunoglobulin-A vasculitis. <i>Scientific Reports</i> , 2021, 11, 11510.	1.6	5
16	Role of the IL33 and IL1RL1 pathway in the pathogenesis of Immunoglobulin A vasculitis. <i>Scientific Reports</i> , 2021, 11, 16163.	1.6	1
17	Imaging Tests in the Early Diagnosis of Giant Cell Arteritis. <i>Journal of Clinical Medicine</i> , 2021, 10, 3704.	1.0	16
18	Severe microscopic polyangiitis limited to the skin. <i>Rheumatology</i> , 2021, , .	0.9	0

#	ARTICLE	IF	CITATIONS
19	Diagnóstico de la arteritis de células gigantes. Medicina Clínica, 2021, 157, 285-287.	0.3	2
20	Cranial and extracranial giant cell arteritis do not have different HLA-DRB1 and HLA-B association in Caucasian individuals. Arthritis Research and Therapy, 2021, 23, 268.	1.6	0
21	Moderate and High Disease Activity Predicts the Development of Carotid Plaque in Rheumatoid Arthritis Patients without Classic Cardiovascular Risk Factors: Six Years Follow-Up Study. Journal of Clinical Medicine, 2021, 10, 4975.	1.0	9
22	Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisyndetase syndrome. Scientific Reports, 2021, 11, 22574.	1.6	4
23	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. Clinical and Experimental Rheumatology, 2021, 39, 105-114.	0.4	4
24	The presence of both HLA-DRB1*04:01 and HLA-B*15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. Clinical and Experimental Rheumatology, 2021, 39 Suppl 129, 21-26.	0.4	3
25	Coexisting sarcoidosis and systemic lupus erythematosus: a case report and literature review. Acta Reumatológica Portuguesa, 2021, 46, 177-185.	0.2	0
26	The presence of both HLA-DRB1[*]04:01 and HLA-B[*]15:01 increases the susceptibility to cranial and extracranial giant cell arteritis. Clinical and Experimental Rheumatology, 2021, 39, 21-26.	0.4	13
27	SCORE2 Assessment in the Calculation of Cardiovascular Risk in Patients with Rheumatoid Arthritis. Diagnostics, 2021, 11, 2363.	1.3	3
28	Efficacy and safety of certolizumab pegol in pregnant women with uveitis. Recommendations on the management with immunosuppressive and biologic therapies in uveitis during pregnancy. Clinical and Experimental Rheumatology, 2021, 39, 105-114.	0.4	17
29	Unmet needs in the management of cardiovascular risk in inflammatory joint diseases. Expert Review of Clinical Immunology, 2020, 16, 23-36.	1.3	16
30	Rituximab in the Treatment of Interstitial Lung Disease Associated with Autoimmune Diseases: Experience from a Single Referral Center and Literature Review. Journal of Clinical Medicine, 2020, 9, 3070.	1.0	16
31	Probability-based algorithm using ultrasound and additional tests for suspected GCA in a fast-track clinic. RMD Open, 2020, 6, e001297.	1.8	29
32	Cranial and extracranial giant cell arteritis share similar HLA-DRB1 association. Seminars in Arthritis and Rheumatism, 2020, 50, 897-901.	1.6	7
33	The Number of Traditional Cardiovascular Risk Factors Is Independently Correlated with Disease Activity in Patients with Psoriatic Arthritis. Medicina (Lithuania), 2020, 56, 415.	0.8	7
34	Misperception of the Cardiovascular Risk in Patients with Rheumatoid Arthritis. International Journal of Environmental Research and Public Health, 2020, 17, 5954.	1.2	3
35	Biologic Therapy in Refractory Non-Multiple Sclerosis Optic Neuritis Isolated or Associated to Immune-Mediated Inflammatory Diseases. A Multicenter Study. Journal of Clinical Medicine, 2020, 9, 2608.	1.0	3
36	The Performance of Vascular Age in the Assessment of Cardiovascular Risk of Patients with Rheumatoid Arthritis. Journal of Clinical Medicine, 2020, 9, 4065.	1.0	2

#	ARTICLE	IF	CITATIONS
37	Endothelial Progenitor Cells as a Potential Biomarker in Interstitial Lung Disease Associated with Rheumatoid Arthritis. <i>Journal of Clinical Medicine</i> , 2020, 9, 4098.	1.0	16
38	The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3.6-Year Prospective Study from a Referral Center of Interstitial Lung Disease and Lung Transplantation. <i>Journal of Clinical Medicine</i> , 2020, 9, 1606.	1.0	22
39	Biologic agents and small-molecule inhibitors in systemic autoimmune conditions: an update. <i>Polish Archives of Internal Medicine</i> , 2020, 131, 171-181.	0.3	13
40	Long-term survival of lung transplantation for interstitial lung disease associated with connective tissue diseases: a study of 26 cases from a referral centre. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 615-620.	0.4	4
41	Giant cell arteritis: more than a cranial disease. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 15-17.	0.4	5
42	Tocilizumab in giant cell arteritis: differences between the GACTA trial and a multicentre series of patients from the clinical practice. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 112-119.	0.4	3
43	Role of IRF5 in the pathogenesis of immunoglobulin-A vasculitis. <i>Clinical and Experimental Rheumatology</i> , 2020, 38 Suppl 124, 182-187.	0.4	0
44	Predictors of positive 18F-FDG PET/CT-scan for large vessel vasculitis in patients with persistent polymyalgia rheumatica. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 48, 720-727.	1.6	63
45	Early large vessel systemic vasculitis in adults. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101424.	1.4	29
46	Treatment of giant cell arteritis. <i>Biochemical Pharmacology</i> , 2019, 165, 230-239.	2.0	15
47	Treatment of polymyalgia rheumatica. <i>Biochemical Pharmacology</i> , 2019, 165, 221-229.	2.0	17
48	Tocilizumab in giant cell arteritis. Observational, open-label multicenter study of 134 patients in clinical practice. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 126-135.	1.6	66
49	The role of biologics in the treatment of giant cell arteritis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 65-72.	1.4	6
50	Drug therapies for polymyalgia rheumatica: a pharmacotherapeutic update. <i>Expert Opinion on Pharmacotherapy</i> , 2018, 19, 1235-1244.	0.9	6
51	Current and emerging diagnosis tools and therapeutics for giant cell arteritis. <i>Expert Review of Clinical Immunology</i> , 2018, 14, 593-605.	1.3	17
52	Molecular imaging in large vessel vasculitis has come to stay. <i>Annals of Translational Medicine</i> , 2018, 6, S2-S2.	0.7	1
53	Vascular endothelial growth factor haplotypes are associated with severe ischaemic complications in giant cell arteritis regardless of the disease phenotype. <i>Clinical and Experimental Rheumatology</i> , 0, , .	0.4	1